Journal of Vascular Surgery
Volume 45, Issue 1, Supplement , Pages S5-S67 , January 2007

Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)

  • L. Norgren

      Affiliations

    • Department of Surgery, University Hospital, Örebro, Sweden
    • Corresponding Author InformationCorrespondence: L. Norgren, Department of Surgery, University Hospital, Örebro, Sweden (e-mail: lars.norgren@orebroll.se) and W.R. Hiatt, University of Colorado School of Medicine, Denver, CO (e-mail: will.hiatt@uchsc.edu)
    • ,
  • W.R. Hiatt

      Affiliations

    • University of Colorado School of Medicine and Colorado Prevention Center, Denver, Colorado
    • ,
  • J.A. Dormandy
    • ,
  • M.R. Nehler
    • ,
  • K.A. Harris
    • ,
  • F.G.R. Fowkes
    • ,
  • on behalf of the TASC II Working Group

References 

  1. TASC . Management of peripheral arterial disease (PAD). TransAtlantic Inter-Society Consensus (TASC). Eur J Vasc Endovasc Surg. 2000;19((Suppl A):):Si–xxviiiS1-250
  2. TASC . Management of Peripheral Arterial Disease (PAD) TransAtlantic Intersociety Consensus (TASC). J Vasc Surg. 2000;31((1 part 2):):S1–S287
  3. TASC . Management of peripheral arterial disease (PAD). TransAtlantic Inter-Society Consensus (TASC). Int Angiol. 2000;19((1 Suppl. 1):):I–XXIV1-304
  4. Clement DL, Boccalon H, Dormandy J, Durand-Zaleski I, Fowkes G, Brown T. A clinical approach to the management of the patient with coronary (Co) and/or carotid (Ca) artery disease who presents with leg ischaemia (Lis). Int Angiol. 2000;19((2):):97–125
  5. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL et al. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extermity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interverntions, Society for Vascular Medicine and Biology, Society of Interventional Raidology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. J Am Coll Cardiol 2006;47:1239-312.
  6. AHCPR. United States Department of Health and Human Services . Agency for Health Care Policy and Research. Acute pain management: operative on medical procedures and trauma. [107]. Rockville MD: AHCPR; 1993;
  7. Criqui MH, Fronek A, Barrett-Connor E, Klauber MR, Gabriel S, Goodman D. The prevalence of peripheral arterial disease in a defined population. Circulation. 1985;71((3):):510–551
  8. Hiatt WR, Hoag S, Hamman RF. Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley Diabetes Study. Circulation. 1995;91((5):):1472–1479
  9. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999–2000. Circulation. 2004;110((6):):738–743
  10. Fowkes FG, Housley E, Cawood EH, Macintyre CC, Ruckley CV, Prescott RJ. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol. 1991;20((2):):384–392
  11. Hirsch A, Criqui M, Treat-Jacobson D, Regensteiner J, Creager M, Olin J, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286((11):):1317–1324
  12. Criqui MH, Vargas V, Denenberg JO, Ho E, Allison M, Langer RD, et al. Ethnicity and peripheral arterial disease: the San Diego Population Study. Circulation. 2005;112((17):):2703–2707
  13. Kullo IJ, Bailey KR, Kardia SL, Mosley TH, Boerwinkle E, Turner ST. Ethnic differences in peripheral arterial disease in the NHLBI Genetic Epidemiology Network of Arteriopathy (GENOA) study. Vasc Med. 2003;8((4):):237–242
  14. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004;141((6):):421–431
  15. Muntner P, Wildman RP, Reynolds K, Desalvo KB, Chen J, Fonseca V. Relationship between HbA1c level and peripheral arterial disease. Diabetes Care. 2005;28((8):):1981–1987
  16. ADA . Peripheral arterial disease in people with diabetes. Diabetes Care. 2003;26((12):):3333–3341
  17. Senti M, Nogues X, Pedro-Botet J, Rubies-Prat J, Vidal-Barraquer F. Lipoprotein profile in men with peripheral vascular disease. Role of intermediate density lipoproteins and apoprotein E phenotypes. Circulation. 1992;85((1):):30–36
  18. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA. 2001;285((19):):2481–2485
  19. O'Hare AM, Vittinghoff E, Hsia J, Shlipak MG. Renal insufficiency and the risk of lower extremity peripheral arterial disease: results from the Heart and Estrogen/Progestin Replacement Study (HERS). J Am Soc Nephrol. 2004;15((4):):1046–1051
  20. McDermott MM, Criqui MH, Greenland P, Guralnik JM, Liu K, Pearce WH, et al. Leg strength in peripheral arterial disease: associations with disease severity and lower-extremity performance. J Vasc Surg. 2004;39((3):):523–530
  21. Widmer L, Biland L. Risk profile and occlusive peripheral arterial disease. Proceedings of 13th International Congress of Angiology. 1985;28
  22. Kannel WB, Skinner JJ, Schwartz MJ, Shurtleff D. Intermittent claudication. Incidence in the Framingham Study. Circulation. 1970;41((5):):875–883
  23. Rothwell PM, Eliasziw M, Gutnikov SA, Warlow CP, Barnett HJ. Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery. Lancet. 2004;363((9413):):915–924
  24. Tunis SR, Bass EB, Steinberg EP. The use of angioplasty, bypass surgery, and amputation in the management of peripheral vascular disease. N Engl J Med. 1991;325((8):):556–562
  25. Dormandy J, Belcher G, Broos P, Eikelboom B, Laszlo G, Konrad P, et al. Prospective study of 713 below-knee amputations for ischaemia and the effect of a prostacyclin analogue on healing. Hawaii Study Group. Br J Surg. 1994;81((1):):33–37
  26. Bhatt D, Steg P, Ohman E, Hirsch A, Ikeda Y, Mas J, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295:180–189
  27. Aronow WS, Ahn C. Prevalence of coexistence of coronary artery disease, peripheral arterial disease, and atherothrombotic brain infarction in men and women > or = 62 years of age. Am J Cardiol. 1994;74((1):):64–65
  28. Dormandy JA, Murray GD. The fate of the claudicant–a prospective study of 1969 claudicants. Eur J Vasc Surg. 1991;5((2):):131–133
  29. Mehler PS, Coll JR, Estacio R, Esler A, Schrier RW, Hiatt WR. Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. Circulation. 2003;107((5):):753–756
  30. Criqui M, Langer R, Fronek A, Feigelson H, Klauber M, McCann T, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326:381–386
  31. Fowkes F, Lee A, Murray G. On behalf of the ABI collaboration. Ankle-brachial index as an independent indicator of mortality in fifteen international population cohort studies. Circulation. 2005;112:3704
  32. CAPRIE . A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348((9038):):1329–1339
  33. HPSCG . MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360((9326):):7–22
  34. Resnick HE, Lindsay RS, McDermott MM, Devereux RB, Jones KL, Fabsitz RR, et al. Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong Heart Study. Circulation. 2004;109((6):):733–739
  35. Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA. 2003;290((1):):86–97
  36. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med. 2005;142((4):):233–239
  37. Tonstad S, Farsang C, Klaene G, Lewis K, Manolis A, Perruchoud AP, et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. Eur Heart J. 2003;24((10):):946–955
  38. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999;340((9):):685–691
  39. Willigendael EM, Teijink JA, Bartelink ML, Peters RJ, Buller HR, Prins MH. Smoking and the patency of lower extremity bypass grafts: a meta-analysis. J Vasc Surg. 2005;42((1):):67–74
  40. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366((9493):):1267–1278
  41. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). Atherosclerosis. 2004;173((2):):381–391
  42. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110((2):):227–239
  43. Smith SC, Blair SN, Bonow RO, Brass LM, Cerqueira MD, Dracup K, et al. AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation. 2001;104((13):):1577–1579
  44. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341((6):):410–418
  45. Blankenhorn DH, Azen SP, Crawford DW, Nessim SA, Sanmarco ME, Selzer RH, et al. Effects of colestipol-niacin therapy on human femoral atherosclerosis. Circulation. 1991;83((2):):438–447
  46. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004;110((23):):3512–3517
  47. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42((6):):1206–1252
  48. ESH/ESC . 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21((6):):1011–1053
  49. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342((3):):145–153
  50. Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch Intern Med. 1991;151((9):):1769–1776
  51. UKPDS . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352((9131):):837–853
  52. DCCT . Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol. 1995;75((14):):894–903
  53. ADA . Standards of medical care in diabetes–2006. Diabetes Care. 2006;29((Suppl. 1):):S4–S42
  54. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366((9493):):1279–1289
  55. Bonaa K, Njolstad I, Ueland P, Schirmer H, Tverdal A, Steigen T, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006;354:1578–1588
  56. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354((15):):1567–1577
  57. ATC . Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J. 2002;324((7329):):71–86
  58. ATC . Collaborative overview of randomised trials of antiplatelet therapy–I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. Br Med J. 1994;308((6921):):81–106
  59. Clagett P, Sobel M, Jackson M, Lip G, Tangelder M, Verhaeghe R. Antithrombotic therapy in peripheral arterial disease: The Seventh ACCP Conference on antithrombotic and thrombolytic therapy. Chest. 2004;126:S609–S626
  60. Neri Serneri GG, Coccheri S, Marubini E, Violi F. Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study. Eur Heart J. 2004;25((20):):1845–1852
  61. Janzon L, Bergqvist D, Boberg J, Boberg M, Eriksson I, Lindgarde F, et al. Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. J Intern Med. 1990;227((5):):301–308
  62. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345((7):):494–502
  63. Bhatt D, Fox K, Hacke W, Berger P, Black H, Boden W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706–1717
  64. Murray CJ, Lauer JA, Hutubessy RC, Niessen L, Tomijima N, Rodgers A, et al. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. Lancet. 2003;361((9359):):717–725
  65. Fischer MA, Avorn J. Economic implications of evidence-based prescribing for hypertension: can better care cost less?. JAMA. 2004;291((15):):1850–1856
  66. Gaspoz JM, Coxson PG, Goldman PA, Williams LW, Kuntz KM, Hunink MG, et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med. 2002;346((23):):1800–1806
  67. Lancaster T, Silagy C, Fowler G. Training health professionals in smoking cessation. Cochrane Database Syst Rev. 2000;(3):):CD000214
  68. Song F, Raftery J, Aveyard P, Hyde C, Barton P, Woolacott N. Cost-effectiveness of pharmacological interventions for smoking cessation: a literature review and a decision analytic analysis. Med Decis Making. 2002;22((Suppl):):S26–S37
  69. Hillsdon M, Foster C, Thorogood M. Interventions for promoting physical activity. Cochrane Database Syst Rev. 2005;(1):):CD003180
  70. Lowensteyn I, Coupal L, Zowall H, Grover SA. The cost-effectiveness of exercise training for the primary and secondary prevention of cardiovascular disease. J Cardiopulm Rehabil. 2000;20((3):):147–155
  71. Jones L, Griffin S, Palmer S, Main C, Orton V, Sculpher M, et al. Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation. Health Technol Assess. 2004;8((38):):iii–iv1-196
  72. Mihaylova B, Briggs A, Armitage J, Parish S, Gray A, Collins R. Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals. Lancet. 2005;365((9473):):1779–1785
  73. Lamy A, Yusuf S, Pogue J, Gafni A. Cost implications of the use of ramipril in high-risk patients based on the Heart Outcomes Prevention Evaluation (HOPE) study. Circulation. 2003;107((7):):960–965
  74. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation. 2004;110((9):):e82–e292
  75. Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina–summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol. 2003;41((1):):159–168
  76. Eagle KA, Berger PB, Calkins H, Chaitman BR, Ewy GA, Fleischmann KE, et al. ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery–executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). J Am Coll Cardiol. 2002;39((3):):542–553
  77. McFalls EO, Ward HB, Moritz TE, Goldman S, Krupski WC, Littooy F, et al. Coronary-artery revascularization before elective major vascular surgery. N Engl J Med. 2004;351((27):):2795–2804
  78. Poldermans D, Boersma E, Bax JJ, Thomson IR, Paelinck B, van de Ven LL, et al. Bisoprolol reduces cardiac death and myocardial infarction in high-risk patients as long as 2 years after successful major vascular surgery. Eur Heart J. 2001;22((15):):1353–1358
  79. Poldermans D, Boersma E, Bax JJ, Thomson IR, van de Ven LL, Blankensteijn JD, et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. N Engl J Med. 1999;341((24):):1789–1794
  80. Kertai MD, Boersma E, Bax JJ, Thomson IR, Cramer MJ, van de Ven LL, et al. Optimizing long-term cardiac management after major vascular surgery: Role of beta-blocker therapy, clinical characteristics, and dobutamine stress echocardiography to optimize long-term cardiac management after major vascular surgery. Arch Intern Med. 2003;163((18):):2230–2235
  81. Adams RJ, Chimowitz MI, Alpert JS, Awad IA, Cerqueria MD, Fayad P, et al. Coronary risk evaluation in patients with transient ischemic attack and ischemic stroke: a scientific statement for healthcare professionals from the Stroke Council and the Council on Clinical Cardiology of the American Heart Association/American Stroke Association. Circulation. 2003;108((10):):1278–1290
  82. Chaturvedi S, Bruno A, Feasby T, Holloway R, Benavente O, Cohen SN, et al. Carotid endarterectomy–an evidence-based review: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2005;65((6):):794–801
  83. Rundback JH, Sacks D, Kent KC, Cooper C, Jones D, Murphy T, et al. Guidelines for the reporting of renal artery revascularization in clinical trials. J Vasc Interv Radiol. 2003;14((9 Pt 2):):S477–S492
  84. Plouin PF, Clement DL, Boccalon H, Dormandy J, Durand-Zaleski I, Fowkes G, et al. A clinical approach to the management of a patient with suspected renovascular disease who presents with leg ischemia. Int Angiol. 2003;22((4):):333–339
  85. McDermott MM, Greenland P, Liu K, Guralnik JM, Criqui MH, Dolan NC, et al. Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment. JAMA. 2001;286((13):):1599–1606
  86. Criqui MH, Fronek A, Klauber MR, Barrett-Connor E, Gabriel S. The sensitivity, specificity, and predictive value of traditional clinical evaluation of peripheral arterial disease: results from noninvasive testing in a defined population. Circulation. 1985;71((3):):516–522
  87. Gibbons RJ, Balady GJ, Bricker JT, Chaitman BR, Fletcher GF, Froelicher VF, et al. ACC/AHA 2002 guideline update for exercise testing: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). J Am Coll Cardiol. 2002;40((8):):1531–1540
  88. Labs KH, Dormandy JA, Jaeger KA, Stuerzebecher C, Hiatt WR. Trans-atlantic conference on clinical trial guidelines in PAOD (Peripheral arterial occlusive disease) clinical trial methodology. Eur J Vasc Endovasc Surg. 1999;18((3):):253–265
  89. Gardner A, Poehlman E. Exercise rehabilitation programs for the treatment of claudication pain: a meta-analysis. JAMA. 1995;274:975–980
  90. Stewart K, Hiatt W, Regensteiner J, Hirsch A. Exercise training for claudication. N Engl J Med. 2002;347((24):):1941–1951
  91. Hiatt W, Wolfel E, Meier R, Regensteiner J. Superiority of treadmill walking exercise vs. strength training for patients with peripheral arterial disease. Implications for the mechanism of the training response. Circulation. 1994;90:1866–1874
  92. Regensteiner J, Ware JJ, McCarthy W, Zhang P, Forbes W, Heckman J, et al. Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials. J Am Geriatr Soc. 2002;50((12):):1939–1946
  93. Dawson D, Cutler B, Hiatt W, Hobson R, Martin J, Bortey E, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med. 2000;109((7):):523–530
  94. Pratt C. Analysis of the cilostazol safety database. Am J Cardiol. 2001;87((12A):):28D–33D
  95. Lehert P, Comte S, Gamand S, Brown TM. Naftidrofuryl in intermittent claudication: a retrospective analysis. J Cardiovasc Pharmacol. 1994;23((Suppl. 3):):S48–S52
  96. Boccalon H, Lehert P, Mosnier M. Effect of naftidrofuryl on physiological walking distance in patients with intermittent claudication. Ann Cardiol Angeiol (Paris). 2001;50((3):):175–182
  97. Kieffer E, Bahnini A, Mouren X, Gamand S. A new study demonstrates the efficacy of naftidrofuryl in the treatment of intermittent claudication. Findings of the Naftidrofuryl Clinical Ischemia Study (NCIS). Int Angiol. 2001;20((1):):58–65
  98. Spengel F, Clement D, Boccalon H, Liard F, Brown T, Lehert P. Findings of the Naftidrofuryl in Quality of Life (NIQOL) European study program. Int Angiol. 2002;21((1):):20–27
  99. Brevetti G, Diehm C, Lambert D. European multicenter study on Propionyl-l-carnitine in intermittent claudication. J Am Coll Cardiol. 1999;34:1618–1624
  100. Hiatt W, Regensteiner J, Creager M, Hirsch A, Cooke J, Olin J, et al. Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication. Am J Med. 2001;110((8):):616–622
  101. Mohler E, Hiatt W, Creager M. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation. 2003;108((12):):1481–1486
  102. Mondillo S, Ballo P, Barbati R, Guerrini F, Ammaturo T, Agricola E, et al. Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. Am J Med. 2003;114((5):):359–364
  103. Girolami B, Bernardi E, Prins M, ten Cate J, Hettiarachchi R, Prandoni P, et al. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. Arch Intern Med. 1999;159((4):):337–345
  104. Hood SC, Moher D, Barber GG. Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials. CMAJ. 1996;155((8):):1053–1059
  105. Moher D, Pham B, Ausejo M, Saenz A, Hood S, Barber G. Pharmacological management of intermittent claudication: a meta- analysis of randomised trials. Drugs. 2000;59((5):):1057–1070
  106. Cosmi B, Conti E, Coccheri S. Anticoagulants (heparin, low molecular weight heparin and oral anticoagulants) for intermittent claudication. Cochrane Database Syst Rev. 2001;CD001999
  107. Coffman J. Vasodilator drugs in peripheral vascular disease. N Engl J Med. 1979;300:713–717
  108. Maxwell AJ, Anderson BE, Cooke JP. Nutritional therapy for peripheral arterial disease: a double-blind, placebo-controlled, randomized trial of HeartBar. Vasc Med. 2000;5((1):):11–19
  109. Hiatt WR, Klepack E, Nehler M, Regensteiner JG, Blue J, Imus J, et al. The effect of inhibition of acyl coenzyme A-cholesterol acyltransferase (ACAT) on exercise performance in patients with peripheral arterial disease. Vasc Med. 2004;9((4):):271–277
  110. Thulesius O, Lundvall J, Kroese A, Stranden E, Hallbook T, Brunes L, et al. Ketanserin in intermittent claudication: effect on walking distance, blood pressure, and cardiovascular complications. J Cardiovasc Pharmacol. 1987;9((6):):728–733
  111. Verstraete M. The PACK trial: morbidity and mortality effects of ketanserin. Prevention of atherosclerotic complications. Vasc Med. 1996;1((2):):135–140
  112. Hiatt WR, Hirsch AT, Cooke JP, Olin JW, Brater DC, Creager MA. Randomized trial of AT-1015 for treatment of intermittent claudication. A novel 5-hydroxytryptamine antagonist with no evidence of efficacy. Vasc Med. 2004;9((1):):18–25
  113. Norgren L, Jawien A, Matyas L, Rieger H, Arita K. the European MCI-9042 Study Group. Sarpogrelate, a 5-HT2A receptor antagonist in intermittent claudication. A phase II European Study. Vasc Med. 2006;11:75–83
  114. Belch J, Bell P, Creissen Dea, Dormandy JA, Kester RC, McCollum RD, et al. Randomised, placebo-controlled, double-blind study evaluating the efficacy and safety of AS-013, a prostaglandin E1 prodrug, in patients with intermittent claudication. Circulation. 1997;95:2298–2302
  115. Lievre M, Morand S, Besse B, Fiessinger J, Boissel J. Oral beraprost sodium, a prostaglandin I(2) analogue, for intermittent claudication: a double-blind, randomized, multicenter controlled trial. Beraprost et Claudication Intermittente (BERCI) Research Group. Circulation. 2000;102((4):):426–431
  116. Mohler E, Hiatt W, Olin J, Wade M, Jeffs R, Hirsch A. Treatment of intermittent claudication with beraprost sodium, an orally active prostaglandin I2 analogue: a double-blinded, randomized, controlled trial. J Am Coll Cardiol. 2003;41((10):):1679–1686
  117. de Backer T, Vander Stichele R, Bogaert M. Buflomedil for intermittent claudication. Cochrane Database Syst Rev. 2001;CD000988
  118. de Backer T, Vander Stichele R, Warie H, Bogaert M. Oral vasoactive medication in intermittent claudication: utile or futile?. Eur J Clin Pharmacol. 2000;56((3):):199–206
  119. Laurora G, Ambrosoli L, Cesarone MR, De Sanctis MT, Incandela L, Marelli C, et al. Treatment of intermittent claudication with defibrotide or mesoglycan. A double blind study. Panminerva Med. 1994;36((2):):83–86
  120. Strano A, Fareed J, Sabba C, Albano O, Allegra C, Carlizza A, et al. A double-blind, multicenter, placebo-controlled, dose comparison study of orally administered defibrotide: preliminary results in patients with peripheral arterial disease. Semin Thromb Hemost. 1991;17((Suppl 2):):228–234
  121. Violi F, Marubini E, Coccheri S, Nenci GG. Improvement of walking distance by defibrotide in patients with intermittent claudication–results of a randomized, placebo-controlled study (the DICLIS study). Defibrotide Intermittent CLaudication Italian Study. Thromb Haemost. 2000;83((5):):672–677
  122. Lederman R, Mendelsohn F, Anderson R, Saucedo J, Tenaglia A, JB H, et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet. 2002;359((9323):):2053–2058
  123. Rajagopalan S, Mohler EI, Lederman R, Mendelsohn F, Saucedo J, Goldman C, et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation. 2003;108((16):):1933–1938
  124. Armstrong DG, Lavery LA. Diabetic foot ulcers: prevention, diagnosis and classification. Am Fam Physician. 1998;57((6):):1325–13321337–8
  125. Reiber GE, Vileikyte L, Boyko EJ, del Aguila M, Smith DG, Lavery LA, et al. Causal pathways for incident lower-extremity ulcers in patients with diabetes from two settings. Diabetes Care. 1999;22((1):):157–162
  126. Armstrong DG, Lavery LA, Kimbriel HR, Nixon BP, Boulton AJ. Activity patterns of patients with diabetic foot ulceration: patients with active ulceration may not adhere to a standard pressure off-loading regimen. Diabetes Care. 2003;26((9):):2595–2597
  127. Moulik PK, Mtonga R, Gill GV. Amputation and mortality in new-onset diabetic foot ulcers stratified by etiology. Diabetes Care. 2003;26((2):):491–494
  128. Strandness DJ, Sumner D. Hemodynamics for surgeons. New York: Grune & Stratton; 1975. p. 278-81.
  129. Franzeck UK, Talke P, Bernstein EF, Golbranson FL, Fronek A. Transcutaneous PO2 measurements in health and peripheral arterial occlusive disease. Surgery. 1982;91((2):):156–163
  130. Smith I, Franks PJ, Greenhalgh RM, Poulter NR, Powell JT. The influence of smoking cessation and hypertriglyceridaemia on the progression of peripheral arterial disease and the onset of critical ischaemia. Eur J Vasc Endovasc Surg. 1996;11((4):):402–408
  131. ADA . Consensus Development Conference on Diabetic Foot Wound Care (American Diabetes Association). Diabetes Care. 1999;22:1354–1360
  132. Nabuurs-Franssen MH, Sleegers R, Huijberts MS, Wijnen W, Sanders AP, Walenkamp G, et al. Total contact casting of the diabetic foot in daily practice: a prospective follow-up study. Diabetes Care. 2005;28((2):):243–247
  133. Lipsky B. International consensus group on diagnosing and treating the infected diabetic foot. A report from the international consensus on diagnosing and treating the infected diabetic foot. Diabetes Metab Res Rev. 2004;20((Suppl 1):):S68–S77
  134. Frykberg R. An evidence based approach to diabetic foot infections. Am J Surg. 2003;186:S44–S54
  135. Nehler MR, Hiatt WR, Taylor LM. Is revascularization and limb salvage always the best treatment for critical limb ischemia?. J Vasc Surg. 2003;37((3):):704–708
  136. Cutson TM, Bongiorni DR. Rehabilitation of the older lower limb amputee: a brief review. J Am Geriatr Soc. 1996;44((11):):1388–1393
  137. Lim RC, Blaisdell FW, Hall AD, Moore WS, Thomas AN. Below-knee amputation for ischemic gangrene. Surg Gynecol Obstet. 1967;125((3):):493–501
  138. Poredos P, Rakovec S, Guzic-Salobir B. Determination of amputation level in ischaemic limbs using tcPO2 measurement. Vasa. 2005;34((2):):108–112
  139. Ruckley CV, Stonebridge PA, Prescott RJ. Skewflap versus long posterior flap in below-knee amputations: multicenter trial. J Vasc Surg. 1991;13((3):):423–427
  140. Siriwardena GJ, Bertrand PV. Factors influencing rehabilitation of arteriosclerotic lower limb amputees. J Rehabil Res Dev. 1991;28((3):):35–44
  141. Hagberg E, Berlin OK, Renstrom P. Function after through-knee compared with below-knee and above-knee amputation. Prosthet Orthot Int. 1992;16((3):):168–173
  142. Houghton AD, Taylor PR, Thurlow S, Rootes E, McColl I. Success rates for rehabilitation of vascular amputees: implications for preoperative assessment and amputation level. Br J Surg. 1992;79((8):):753–755
  143. Stirnemann P, Walpoth B, Wursten HU, Graber P, Parli R, Althaus U. Influence of failed arterial reconstruction on the outcome of major limb amputation. Surgery. 1992;111((4):):363–368
  144. McWhinnie DL, Gordon AC, Collin J, Gray DW, Morrison JD. Rehabilitation outcome 5 years after 100 lower-limb amputations. Br J Surg. 1994;81((11):):1596–1599
  145. Nehler MR, Coll JR, Hiatt WR, Regensteiner JG, Schnickel GT, Klenke WA, et al. Functional outcome in a contemporary series of major lower extremity amputations. J Vasc Surg. 2003;38((1):):7–14
  146. Balzer K, Bechara G, Bisler H, Clevert H, Diehm C, Heisig G, et al. Placebo-kontrollierte, doppel-blinde Multicenterstudie zur Wirksamkeit von Iloprost bei der Behandlung ischämischer Ruheschmerzen von Patienten mit peripheren arterillen Durchblutungsstörungen. Vasa. 1987;20((Suppl):):379–381
  147. Brock FE, Abri O, Baitsch G, Bechara G, Beck K, Corovic D, et al. Iloprost in the treatment of ischemic tissue lesions in diabetics. Results of a placebo-controlled multicenter study with a stable prostacyclin derivative. Schweiz Med Wochenschr. 1990;120((40):):1477–1482
  148. Diehm C, Abri O, Baitsch G, Bechara G, Beck K, Breddin HK, et al. Iloprost, a stable prostacyclin derivative, in stage 4 arterial occlusive disease. A placebo-controlled multicenter study. Dtsch Med Wochenschr. 1989;114((20):):783–788
  149. Diehm C, Hibsch-Miller C, Stammler F. Intravenose prostaglandin E1-therapie bei patienten mit peripherer arterieller verschlusskrankheit (AVK) im Stadium III: Eine doppelblinde, placebo-kontrollierte studie. In:  Heinrich H,  Bohme H,  Rogatti W editor. Prostaglandin E1-Wirkungen und therapeutische Wirksamheit. Heidelberg: Springer-Verlag; 1988;p. 133–143
  150. Ciprostene Study Group . The effect of ciprostene in patients with peripheral vascular disease (PVD) characterized by ischemic ulcers. J Clin Pharmacol. 1991;31:81–87
  151. UK Severe Limb Ischemia Study Group . Treatment of limb threatening ischemia with intravenous Iloprost: A randomised double-blind placebo controlled study. Eur J Vasc Surg. 1991;5:511–516
  152. Guilmot J, Diot E for the French Iloprost Study Group. Treatment of lower limb ischaemia due to atherosclerosis in diabetic and nondiabetic patients with iloprost, a stable analoque of prostacyclin: results of a French Multicentre trial. Drug Invest. 1991;3:351–359
  153. Norgren L, Alwmark A, Angqvist KA, Hedberg B, Bergqvist D, Takolander R, et al. A stable prostacyclin analogue (iloprost) in the treatment of ischaemic ulcers of the lower limb. A Scandinavian-Polish placebo controlled, randomised multicenter study. Eur J Vasc Surg. 1990;4((5):):463–467
  154. Sakaguchi S. Prostaglandin E1 intra-arterial infusion therapy in patients with ischemic ulcer of the extremities. Int Angiol. 1984;3:39–42
  155. Brass EP, Anthony R, Dormandy J, Hiatt WR, Jiao J, Nakanishi A, et al. Parenteral therapy with lipo-ecraprost, a lipid-based formulation of a PGE1 analog, does not alter six-month outcomes in patients with critical leg ischemia. J Vasc Surg. 2006;43((4):):752–759
  156. Dorffler-Melly J, Koopman MM, Adam DJ, Buller HR, Prins MH. Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery. Cochrane Database Syst Rev. 2003;(3):):CD000535
  157. Smith FB, Bradbury AW, Fowkes FG. Intravenous naftidrofuryl for critical limb ischaemia. Cochrane Database Syst Rev. 2000;(2):):CD002070
  158. European Study Group . Intravenous pentoxifyllin. Eur J Vasc Endovasc Surg. 1995;9:426–436
  159. Norwegian Pentoxifyllin Multicenter Trial Group . Efficacy and clinical tolerance of parenteral pentoxifyllin. Int Angiol. 1996;15:75–80
  160. Kranke Pea. Cochrane Database Syst Rev. 2004;CD004123
  161. Ubbink DT, Vermeulen H. Spinal cord stimulation for non-reconstructable chronic critical leg ischaemia. Cochrane Database Syst Rev. 2003;(3):):CD004001
  162. Cardenas DD, Haselkorn JK, McElligott JM, Gnatz SM. A bibliography of cost-effectiveness practices in physical medicine and rehabilitation: AAPM&R white paper. Arch Phys Med Rehabil. 2001;82((5):):711–719
  163. Oostenbrink JB, Tangelder MJ, Busschbach JJ, van Hout BA, Buskens E, Algra A, et al. Cost-effectiveness of oral anticoagulants versus aspirin in patients after infrainguinal bypass grafting surgery. J Vasc Surg. 2001;34((2):):254–262
  164. Sarac TP, Hilleman D, Arko FR, Zarins CK, Ouriel K. Clinical and economic evaluation of the trellis thrombectomy device for arterial occlusions: preliminary analysis. J Vasc Surg. 2004;39((3):):556–559
  165. Whatling PJ, Gibson M, Torrie EP, Magee TR, Galland RB. Iliac occlusions: stenting or crossover grafting? An examination of patency and cost. Eur J Vasc Endovasc Surg. 2000;20((1):):36–40
  166. Wixon CL, Mills JL, Westerband A, Hughes JD, Ihnat DM. An economic appraisal of lower extremity bypass graft maintenance. J Vasc Surg. 2000;32((1):):1–12
  167. Baumgartner I, Pieczek A, Manor O, Blair R, Kearney M, Walsh K, et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation. 1998;97((12):):1114–1123
  168. Yla-Herttuala S, Alitalo K. Gene transfer as a tool to induce therapeutic vascular growth. Nat Med. 2003;9((6):):694–701
  169. Tateishi-Yuyama E, Matsubara H, Murohara T, Ikeda U, Shintani S, Masaki H, et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet. 2002;360((9331):):427–435
  170. Norgren L. Pharmacotherapy for critical limb ischaemia. Diabetes Metab Res Rev. 2000;16((Suppl 1):):S37–S41
  171. Collinson DJ, Donnelly R. Therapeutic angiogenesis in peripheral arterial disease: can biotechnology produce an effective collateral circulation?. Eur J Vasc Endovasc Surg. 2004;28((1):):9–23
  172. Berridge D, Kessel D, Robertson I. Surgery versus thrombolysis for initial management of acute limb ischaemia. Cochrane Database Syst Rev. 2002;CD002784(1)
  173. Campbell W, Ridler B, Szymanska T. Current management of acute leg ischaemia: results of an audit by the Vascular Surgical Society of Great Britain and Ireland. Br J Surg. 1998;85:1498–1503
  174. Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity. The STILE trial. Ann Surg. 1994;220:251–266
  175. Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg. 1997;26((3):):517–538
  176. Kuukasjarvi P, Salenius J. Perioperative outcome of acute lower limb ischaemia on the basis of the national vascular registry. The Finnvasc Study Group. Eur J Vasc Surg. 1994;8:578–583
  177. Eliason JL, Wainess RM, Proctor MC, Dimick JB, Cowan JA, Upchurch GR, et al. A national and single institutional experience in the contemporary treatment of acute lower extremity ischemia. Ann Surg. 2003;238((3):):382–389discussion 389–390
  178. Ouriel K, Shortell C, DeWeese J, Green R, Francis C, Azodo M, et al. A comparison of thrombolytic therapy with operative revascularization in the initial treatment of acute peripheral arterial ischemia. J Vasc Surg. 1994;19:1021–1030
  179. Ouriel K, Veith F, Sasahara A. A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. Thrombolysis or Peripheral Arterial Surgery (TOPAS) Investigators. N Engl J Med. 1998;338:1105–1111
  180. Korn P, Khilnani NM, Fellers JC, Lee TY, Winchester PA, Bush HL, et al. Thrombolysis for native arterial occlusions of the lower extremities: clinical outcome and cost. J Vasc Surg. 2001;33((6):):1148–1157
  181. Saket RR, Razavi MK, Padidar A, Kee ST, Sze DY, Dake MD. Novel intravascular ultrasound-guided method to create transintimal arterial communications: initial experience in peripheral occlusive disease and aortic dissection. J Endovasc Ther. 2004;11((3):):274–280
  182. Becker GJ, Katzen BT, Dake MD. Noncoronary angioplasty. Radiology. 1989;170((3 Pt 2):):921–940
  183. Rutherford R, Durham J. Percutaneous ballon angioplasty for arteriosclerosis obliterans: long term results. In:  Yao J,  Pearce W editor. Techniques in Vascular Surgery. Philadelphia: Saunders;; 1992;p. 329–345
  184. Murphy TP, Ariaratnam NS, Carney WI, Marcaccio EJ, Slaiby JM, Soares GM, et al. Aortoiliac insufficiency: long-term experience with stent placement for treatment. Radiology. 2004;231((1):):243–249
  185. Timaran CH, Stevens SL, Freeman MB, Goldman MH. External iliac and common iliac artery angioplasty and stenting in men and women. J Vasc Surg. 2001;34((3):):440–446
  186. Tetteroo E, van der Graaf Y, Bosch JL, van Engelen AD, Hunink MG, Eikelboom BC, et al. Randomised comparison of primary stent placement versus primary angioplasty followed by selective stent placement in patients with iliac-artery occlusive disease. Dutch Iliac Stent Trial Study Group. Lancet. 1998;351((9110):):1153–1159
  187. Klein WM, van der Graaf Y, Seegers J, Moll FL, Mali WP. Long-term cardiovascular morbidity, mortality, and reintervention after endovascular treatment in patients with iliac artery disease: The Dutch Iliac Stent Trial Study. Radiology. 2004;232((2):):491–498
  188. Bosch JL, Hunink MG. Meta-analysis of the results of percutaneous transluminal angioplasty and stent placement for aortoiliac occlusive disease. Radiology. 1997;204((1):):87–96
  189. Ponec D, Jaff MR, Swischuk J, Feiring A, Laird J, Mehra M. The Nitinol SMART stent vs Wallstent for suboptimal iliac artery angioplasty: CRISP-US Trial results. J Vasc Interv Radiol. 2004;15((9):):911–918
  190. Reed A, Conte M, Donaldson M, Mannick J, Whittemore A, Belkin M. The impact of patient age and aortic size on the results of aortobifemoral bypass grafting. J Vasc Surg. 2003;37:1219–1225
  191. de Vries S, Hunink M. Results of aortic bifurcation grafts for aortoiliac occlusive disease: a meta-analysis. J Vasc Surg. 1997;26((4):):558–569
  192. Muradin G, Bosch J, Stijnen T, Hunink M. Balloon dilation and stent implantation for treatment of femoropopliteal arterial disease: meta-analysis. Radiology. 2001;221((1):):137–145
  193. London N, Srinivasan R, Naylor A, Hartshorne T, Ratliff D, Bell P, et al. Subintimal angioplasty of femoropopliteal artery occlusions: the long-term results. Eur J Vasc Surg. 1994;8((2):):148–155
  194. Desgranges P, Boufi M, Lapeyre M, Tarquini G, van Laere O, Losy F, et al. Subintimal angioplasty: feasible and durable. Eur J Vasc Endovasc Surg. 2004;28((2):):138–141
  195. Cejna M, Thurnher S, Illiasch H, Horvath W, Waldenberger P, Hornik K, et al. PTA versus Palmaz stent placement in femoropopliteal artery obstructions: a multicenter prospective randomized study. J Vasc Interv Radiol. 2001;12((1):):23–31
  196. Grimm J, Muller-Hulsbeck S, Jahnke T, Hilbert C, Brossmann J, Heller M. Randomized study to compare PTA alone versus PTA with Palmaz stent placement for femoropopliteal lesions. J Vasc Interv Radiol. 2001;12((8):):935–942
  197. Vroegindeweij D, Vos L, Tielbeek A, Buth J, van der Bosch H. Balloon angioplasty combined with primary stenting versus balloon angioplasty alone in femoropopliteal obstructions: A comparative randomized study. Cardiovasc Intervent Radiol. 1997;20((6):):420–425
  198. Schillinger M, Exner M, Mlekusch W, Rumpold H, Ahmadi R, Sabeti S, et al. Vascular inflammation and percutaneous transluminal angioplasty of the femoropopliteal artery: association with restenosis. Radiology. 2002;225((1):):21–26
  199. Schillinger M, Sabeti S, Loewe C, Dick P, Amighi J, Mlekusch W, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 2006;354((18):):1879–1888
  200. Wolf G, Wilson S, Cross A, Deupree R, Stason W. Surgery or balloon angioplasty for peripheral vascular disease: a randomized clinical trial. Principal investigators and their Associates of Veterans Administration Cooperative Study Number 199. J Vasc Interv Radiol. 1993;4((5):):639–648
  201. Adam DJ, Beard JD, Cleveland T, Bell J, Bradbury AW, Forbes JF, et al. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet. 2005;366((9501):):1925–1934
  202. Conte M, Belkin M, Upchurch G, Mannick J, Whittemore A, Donaldson M. Impact of increasing comorbidity on infrainguinal reconstruction: a 20 year perspective. Ann Surg. 2001;233:445–452
  203. Lam E, Landry G, Edwards J, Yeager R, Taylor L, Moneta G. Risk factors for autogenous infrainguinal bypass occlusion in patients with prosthetic inflow grafts. J Vasc Surg. 2004;39:336–342
  204. Albers M, Battistella V, Romiti M, Rodrigues A, Pereira C. Meta-analysis of polytetrafluoethylene bypass grafts to infrapopliteal arteries. J Vasc Surg. 2003;37:1263–1269
  205. Jackson MR, Belott TP, Dickason T, Kaiser WJ, Modrall JG, Valentine RJ, et al. The consequences of a failed femoropopliteal bypass grafting: comparison of saphenous vein and PTFE grafts. J Vasc Surg. 2000;32((3):):498–504504–5
  206. Green R, Abbott W, Matsumoto T, Wheeler JR, Miller N, Veith FJ, et al. Prosthetic above-knee femoropopliteal bypass grafting: five-year results of a randomized trial. J Vasc Surg. 2000;31:417–425
  207. AbuRahma AF, Robinson PA, Holt SM. Prospective controlled study of polytetrafluoroethylene versus saphenous vein in claudicant patients with bilateral above knee femoropopliteal bypasses. Surgery. 1999;126((4):):594–601[discussion 601–602]
  208. Johnson WC, Lee KK. A comparative evaluation of polytetrafluoroethylene, umbilical vein, and saphenous vein bypass grafts for femoral-popliteal above-knee revascularization: a prospective randomized Department of Veterans Affairs cooperative study. J Vasc Surg. 2000;32((2):):268–277
  209. Klinkert P, van Dijk PJ, Breslau PJ. Polytetrafluoroethylene femorotibial bypass grafting: 5-year patency and limb salvage. Ann Vasc Surg. 2003;17((5):):486–491
  210. Hamsho A, Nott D, Harris PL. Prospective randomised trial of distal arteriovenous fistula as an adjunct to femoro-infrapopliteal PTFE bypass. Eur J Vasc Endovasc Surg. 1999;17((3):):197–201
  211. Griffith C, Nagy J, Black D, Stonebridge P. Randomized clinical trial of distal anastomotic interposition vein cuff in infrainguinal polytetrafluoethylene bypass grafting. Br J Surg. 2004;91:560
  212. Davies AH, Hawdon AJ, Sydes MR, Thompson SG. Is duplex surveillance of value after leg vein bypass grafting? Principal results of the Vein Graft Surveillance Randomised Trial (VGST). Circulation. 2005;112((13):):1985–1991
  213. Baldwin Z, Pearce B, Curi M, Desai T, McKinsey J, Bassiouny H, et al. Limb salvage following infrainguinal bypass graft failure. J Vasc Surg. 2004;39:951–957
  214. Tangelder M, Lawson J, Algra A, Eikelboom B. Systematic review of randomized controlled trials of aspirin and oral anticoagulants in prevention of graft occlusion and ischemic events after infrainguinal bypass surgery. J Vasc Surg. 1999;30:701–709
  215. Girolami B, Bernardi E, Prins M, ten Cate J, Prandoni P, Simioni P, et al. Antiplatelet therapy and other interventions after revascularization procedures in patients with peripheral arterial disease: a meta-analysis. Eur J Vasc Endovasc Surg. 2000;19:370–380
  216. Dorffler-Melly J, Buller H, Koopman M, Adam D, Prins M, et al. Antithrombotic agents for preventing thrombosis after peripheral bypass surgery. Cochrane Database Syst Rev. 2003;CD000536
  217. Visser K, Idu MM, Buth J, Engel GL, Hunink MG. Duplex scan surveillance during the first year after infrainguinal autologous vein bypass grafting surgery: costs and clinical outcomes compared with other surveillance programs. J Vasc Surg. 2001;33((1):):123–130
  218. Duda S, Pusich B, Richter G, Landwehr P, Oliva V, Tielbeek A, et al. Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: six-month results. Circulation. 2002;106((12):):1505–1509
  219. Saxon R, Coffman J, Gooding J, Natuzzi E, Ponec D. Long-term results of ePTFE stent-graft versus angioplasty in the femoropopliteal artery: single center experience from a prospective, randomized trial. J Vasc Interv Radiol. 2003;14((3):):303–311
  220. Minar E, Pokrajac B, Maca T, Ahmadi R, Fellner C, Mittlbock M, et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study. Circulation. 2000;102((22):):2694–2699
  221. Rutherford RB, Lowenstein DH, Klein MF. Combining segmental systolic pressures and plethysmography to diagnose arterial occlusive disease of the legs. Am J Surg. 1979;138((2):):211–218
  222. Koelemay MJ, Legemate DA, Reekers JA, Koedam NA, Balm R, Jacobs MJ. Interobserver variation in interpretation of arteriography and management of severe lower leg arterial disease. Eur J Vasc Endovasc Surg. 2001;21((5):):417–422
  223. de Vries M, Nijenhuis RJ, Hoogeveen RM, de Haan MW, van Engelshoven JM, Leiner T. Contrast-enhanced peripheral MR angiography using SENSE in multiple stations: feasibility study. J Magn Reson Imaging. 2005;21((1):):37–45
  224. Vogt FM, Ajaj W, Hunold P, Herborn CU, Quick HH, Debatin JF, et al. Venous compression at high-spatial-resolution three-dimensional MR angiography of peripheral arteries. Radiology. 2004;233((3):):913–920
  225. Dorweiler B, Neufang A, Schmiedt W, Oelert H. Pedal arterial bypass for limb salvage in patients with diabetes mellitus. Eur J Vasc Endovasc Surg. 2002;24((4):):309–313
  226. Jakobs TF, Wintersperger BJ, Becker CR. MDCT-imaging of peripheral arterial disease. Semin Ultrasound CT MR. 2004;25((2):):145–155
  227. Ota H, Takase K, Igarashi K, Chiba Y, Haga K, Saito H, et al. MDCT compared with digital subtraction angiography for assessment of lower extremity arterial occlusive disease: importance of reviewing cross-sectional images. AJR Am J Roentgenol. 2004;182((1):):201–209

PII: S0741-5214(06)02296-8

doi: 10.1016/j.jvs.2006.12.037

Journal of Vascular Surgery
Volume 45, Issue 1, Supplement , Pages S5-S67 , January 2007

Article Tools

* Image Usage & Resolution